BERKELEY HEIGHTS, N.J., June 2, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) today announced interim results that show a high objective response rate in an ongoing trial using tesetaxel as initial chemotherapy in women with recurrent breast cancer. The U.S. trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY. The data were released in conjunction with a presentation at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Tesetaxel is the leading oral taxane in clinical development.
